We are live on ! Find out more
ATRA icon

Atara Biotherapeutics
ATRA

140 hedge funds and large institutions have $1.06B invested in Atara Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 14

126% more call options, than puts

Call options by funds: $1.76M | Put options by funds: $778K

41% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 37

15% more funds holding

Funds holding: 122 → 140 (+18)

0.1% more ownership

Funds ownership: 4.34% → 4.44% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6% less capital invested

Capital invested by funds: $1.13B → $1.06B (-$65.6M)

Holders
140
Holders Change
+18
Holders Change %
+14.75%
% of All Funds
2.82%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
33
Increased
52
Reduced
37
Closed
14
Calls
$1.76M
Puts
$778K
Net Calls
+$983K
Net Calls Change
+$227K

Top Buyers

1
WA
Wasatch Advisors
Utah
+$29.7M
2
JP Morgan Chase
JP Morgan Chase
New York
+$19.4M
3
BlackRock
BlackRock
New York
+$10.4M
4
Morgan Stanley
Morgan Stanley
New York
+$7.25M
5
IC
Ikarian Capital
Texas
+$5.81M

Top Sellers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$11.3M
2
CCM
Consonance Capital Management
New York
-$7.53M
3
Marshall Wace
Marshall Wace
United Kingdom
-$6.77M
4
SPC
Slate Path Capital
New York
-$6.12M
5
Goldman Sachs
Goldman Sachs
New York
-$4.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
LJHT
126
Laurie J. Hall Trustee
$7K +$7.49K +22 New
CG
127
Cutler Group
California
$6K +$6.81K +20 New
RWA
128
Ropes Wealth Advisors
Massachusetts
$5K – – –
ST
129
Smithfield Trust
Pennsylvania
$5K – – –
Daiwa Securities Group
130
Daiwa Securities Group
Japan
$5K +$1.36K +4 +33%
GWM
131
Geneos Wealth Management
Colorado
$4K – – –
US Bancorp
132
US Bancorp
Minnesota
$4K +$1.02K +3 +38%
SFS
133
Sowell Financial Services
Arkansas
$4K +$1.36K +4 +50%
Millennium Management
134
Millennium Management
New York
$3.93K +$4.13M +12,137 New
PA
135
Parallel Advisors
California
$3K – – –
EI
136
Ellevest Inc
New York
$2K +$681 +2 +67%
LC
137
Lindbrook Capital
California
$1K -$4.09K -12 -86%
TWA
138
TCI Wealth Advisors
Arizona
$1K – – –
ABC
139
Associated Banc-Corp
Wisconsin
$1K +$1.02K +3 New
PCM
140
Prelude Capital Management
New York
$1K +$1.36K +4 New
Assenagon Asset Management
141
Assenagon Asset Management
Luxembourg
– -$11.3M -30,948 Closed
SPC
142
Slate Path Capital
New York
– -$6.12M -16,800 Closed
PCM
143
Pinz Capital Management
New York
– -$2.35M -6,444 Closed
Federated Hermes
144
Federated Hermes
Pennsylvania
– -$1.94M -5,330 Closed
Point72 Asset Management
145
Point72 Asset Management
Connecticut
– -$1.93M -5,310 Closed
MWNA
146
Marshall Wace North America
New York
– -$1.43M -3,926 Closed
PGH
147
Partners Group Holding
Switzerland
– -$1.32M -3,616 Closed
Acadian Asset Management
148
Acadian Asset Management
Massachusetts
– -$846K -2,323 Closed
SAMH
149
Shanda Asset Management Holdings
British Virgin Islands
– -$545K -1,497 Closed
MCM
150
Moore Capital Management
New York
– -$364K -1,000 Closed
3 4 5
6
7

ATRA Hedge Fund Activity: Q3 2020 in Review

140 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2020, worth a combined $1.06B — down 5.8% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ATRA positions and 14 closed out — a net gain of 19 holders — while 52 added to existing stakes and 37 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $29.7M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $11.3M sold.

  • 140 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2020, up from 122 in Q2 2020.
  • Funds reported $1.06B of Atara Biotherapeutics stock for Q3 2020, down 5.8% quarter-over-quarter.
  • 33 funds opened new Atara Biotherapeutics positions in Q3 2020 and 14 closed out, a net change of +19 holders.
  • The largest Atara Biotherapeutics buyer in Q3 2020 was Wasatch Advisors, an estimated $29.7M added.
  • The largest Atara Biotherapeutics seller in Q3 2020 was Assenagon Asset Management, an estimated $11.3M sold.

Based on aggregated 13F filings for Q3 2020.